Hypofractionated postoperative stereotactic radiotherapy for large resected brain metastases.
Brain cavities
Brain metastases
Cavité opératoire
Grand volume
Hypofractionated stereotaxtic radiotherapy
Large resected metastasis
Métastases cérébrales
Radiothérapie stéréotaxique
Radiothérapie stéréotaxique hypofractionnée
Stereotactic radiotherapy
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
06
2022
revised:
10
07
2022
accepted:
16
07
2022
medline:
5
4
2023
pubmed:
9
9
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
The aim of the present retrospective study was to report outcomes after hypofractionated stereotactic radiotherapy (HSRT) for resected brain metastases (BM). We reviewed results of patients with resected BM treated with postoperative HSRT (3×7.7Gy to the prescription isodose 70%) between May 2013 and June 2020. Local control (LC), distant brain control (DBC), overall survival (OS), leptomeningeal disease relapse (LMDR), and radiation necrosis (RN) occurrence were reported. Twenty-two patients with 23 brain cavities were included. Karnofsky Performance status (KPS) was≥70 in 77.3%. Median preoperative diameter was 37mm [21.0-75.0] and median planning target volume (PTV) was 23 cm HSRT is the most widely used scheme for larger brain cavities after surgery. The optimal dose and scheme remain to be defined as well as the optimal delay between postoperative SRT and surgery. Dose escalation may be necessary, especially in case of subtotal resection.
Identifiants
pubmed: 36075831
pii: S1278-3218(22)00158-5
doi: 10.1016/j.canrad.2022.07.006
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-95Informations de copyright
Copyright © 2022 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.